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A B S T R A C T
Purpose
Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this
burden represents a paramount treatment objective in the development of MPN-directed
therapies. We aimed to assess the utility of an abbreviated symptom score for the most pertinent
and representative MPN symptoms for subsequent serial use in assessing response to therapy.
Patients and Methods
The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF
TSS) was calculated as the mean score for 10 items from two previously validated scoring
systems. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching,
bone pain, abdominal discomfort, weight loss, and fevers.
Results
MPN-SAF TSS was calculable for 1,408 of 1,433 patients with MPNs who had a mean score of
21.2 (standard deviation [SD], 16.3). MPN-SAF TSS results significantly differed among MPN
disease subtypes (P  .001), with a mean of 18.7 (SD, 15.3), 21.8 (SD, 16.3), and 25.3 (SD, 17.2)
for patients with essential thrombocythemia, polycythemia vera, and myelofibrosis, respectively.
The MPN-SAF TSS strongly correlated with overall quality of life (QOL; r  0.59; P  .001) and
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30
(EORTC QLQ-C30) functional scales (all P  .001 and absolute r  0.50 except social functioning
r  0.48). No significant trends were present when comparing therapy subgroups. The MPN-SAF
TSS had excellent internal consistency (Cronbach’s   .83). Factor analysis identified a single
underlying construct, indicating that the MPN-SAF TSS is an appropriate, unified scoring method.
Conclusion
The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with
demonstrated clinical utility in the largest prospective MPN symptom study to date. This new
prospective scoring method may be used to assess MPN symptom burden in both clinical practice
and trial settings.
J Clin Oncol 30. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Myeloproliferative neoplasms (MPNs) represent a
unique, heterogeneous grouping of clonal or oligo-
clonal hemopathies characterized by the prolifera-
tion and accumulation of mature myeloid cells.
Categorized by theWHO in 2008, MPN subgroups
currently encompass essential thrombocythemia
(ET), polycythemia vera (PV), and myelofibrosis
(MF). Notably, MF may arise either as primary or
antecedent to ET and PV. The clinical presentation
of MPNs is dependent on the MPN subtype. Initial
symptomsmay include erythrocytosis, leukocytosis,
thrombocytosis, and variable degrees of cytopenias.
Over time, patientsmay advance tomassive spleno-
megaly, extramedullary hematopoiesis, cachexia,
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vascular complications, constitutional symptoms, and risk for trans-
formation to acute myeloid leukemia.Mortality rates are characteris-
tically dependent on the subtype ofMPN, ranging from a normal life
expectancy in ET to 5 to 7 years inMF.
Historically, treatment options have been limited and have been
primarily focused on symptom palliation and prevention of end-
organ dysfunction. The 2005 groundbreaking discovery of the JAK2
V617F mutation in multipotent MPN progenitor cells presented a
new therapeutic venue for treatment. JAK2 inhibitors rapidly came
under focus for clinical development. Several JAK2 inhibitors have
since emerged that boast effectiveness in reducing spleen size and
constitutional symptoms1 while improving anemia,2 exercise toler-
ance, and weight gain.2 Ruxolitinib, the first JAK2 inhibitor to obtain
approval by the US Food and Drug Administration, was released in
November 2011. With the rapid expansion of JAK2-directed thera-
pies, it became obvious that a formal symptom evaluation tool was
necessary to provide an accurate assessment of disease burden while
allowing nonrandomized comparisons between therapeutic agents.
Our group had previously conducted a survey among 1,179 pa-
tients withMPN, the results of which suggested thatMPN symptoms
significantly compromise social functioning, physical activity, inde-
pendencewith daily tasks, and global quality of life (QOL).3 From this
work, the Myelofibrosis Symptom Assessment Form (MF-SAF) was
derived,4 an instrument measuring disease impact among patients
with MF. This form was later expanded into the Myeloproliferative
Neoplasm Symptom Assessment Form (MPN-SAF),5 a 17-item in-
strumentmonitoring themost debilitating symptomsamongpatients
with MPNs. This instrument has since been validated in English,
Italian, Swedish, German, French, Spanish, and Dutch. This survey
was ultimately co-administered with the 10-itemBrief Fatigue Inven-
tory (BFI).6
Evaluation of the MPN-SAF in clinical practice suggested that
international implementation would necessitate modification of the
instrument to includeanabbreviatedversion that focusedon themost
representative andclinically relevantMPNsymptoms.Thepurposeof
this study was to construct theMPN-SAF total symptom score (TSS)
by applying the 10 items deemedmost clinically important and char-
acteristicofMPNsymptoms. It is our aimthat this revised toolbeused
to provide an expedient, accurate assessment of MPN symptom bur-
den and guide subsequent therapy decisions.
PATIENTS AND METHODS
Initial MPN-SAF Survey Administration
By using the previously validated BFI and MPN-SAF, we sought to
reduce survey length and improve ease of administration by creating an ab-
breviated instrumentconsistingof themostpertinentandrepresentativeMPN
symptoms. As detailed in previous publications, translations of theMPN-SAF
were created by using the patient-reported outcome translation method.7
Using our existing database of 1,433 patients withMPNs, we analyzed patient
responses and condensed the survey to include the 10 items that most closely
correlated with symptom burden.
International collaborators prospectively administered the survey for
self-completion to patients during an initial clinic visit. Patients were accrued
prospectively from a variety of practice settings, including private practice,
academic centers, and government-funded medical centers in Argentina,
France, Germany, Italy, the Netherlands, Puerto Rico, Spain, Sweden, United
Kingdom, Uruguay, and the United States from November 2009 to January
2011. Approval for this researchwas given by all institutional review boards at
all participating locations before the patients provided informed consent and
before the survey was implemented.
Patients were queried on symptom manifestations by using the BFI,6
MPN-SAF,4 and the European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30).8 Physicians
independently provided information on patient-specific disease features, de-
mographics, treatments, complications, and perceptions of six disease-related
symptoms. Specifically, physicians were queried on patient’s severity of night
sweats, fevers, fatigue, weight loss, bone pain, and pruritus on a scale of 0
(absent/as good as it can be) to 10 (worst imaginable/as bad as it can be).
Languagevalidationandsurveycreationaredetailed inpreviouspublications.5
Participants completed all survey items in the native language of their respec-
tive country.
MPN-SAF TSS Construction
The TSS items chosen were the nine most clinically relevant symptoms
from the 17-item MPN-SAF. MPN-SAF TSS items included “worst fatigue”
from the BFI plus nine items from the MPN-SAF—concentration, early
satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort,
weight loss, and fever—scored on a 0 (absent/as good as it can be) to 10 (worst
imaginable/as bad as it can be) linear analog self-assessment scale (Data Sup-
plement).QOL scoresweredefined as “clinically deficient” if scoreswere rated
asat least 4of10ona0-to-10 scoring system. Inaddition,MPN-SAFTSS items
were designated as “moderate” if symptoms were rated as 4 of 10 or 6 of
10 and as “severe” if symptoms were rated as  7 of 10. For patients who
completed at least six of these 10 items on the BFI and MPN-SAF, the MPN
TSS was computed as the average of the observed items multiplied by 10 to
achieve a 0-to-100 scale. The MPN-SAF TSS thus had a possible range of 0
to 100.
Data Analysis
MPN-SAF TSS results were compared betweenMPN disease groups by
using analysis of variance (ANOVA) F-tests to comparemeans and 2 tests to
compare incidences (score  0). For assessing known groups validity, the
MPN-SAF TSS was compared between known groups (MPN disease type,
clinically deficient patient-reported QOL, and number of common MPN
symptoms endorsed by the physician [to be considered “endorsed,” the phy-
sician was required to rate the symptom 2 of 6]) by using ANOVA F-tests.
For assessing convergent validity, Pearson correlations were computed be-
tween the MPN-SAF TSS and alternate measures of disease burden (EORTC
QLQ-C30 functional and symptom scales, patient-reported overall QOL, and
physicians’ symptom ratings), and absolute correlations more than 0.5 were
considered as at least amoderate level of correlation. Internal consistency was
evaluated by calculating Cronbach’s , which was considered as indicating
good internal consistency with a value more than .7. Construct validity was
evaluated by using principal axis factoring analysis. Eigenvalues more than 1
were considered as meaningful factors. P values less than .05 were considered
statistically significant throughout. Statistical software used for these analyses
included SAS, version 9 (SAS Institute, Cary, NC).
RESULTS
Patient Demographic and Disease Characteristics
In all, 1,433 patients withMPNwere prospectively enrolled (Ar-
gentina,22;France,482;Germany,59; Italy, 186; theNetherlands,236;
United Kingdom, 57; United States [including Puerto Rico], 112;
Spain, 157; Sweden, 114; andUruguay, 8). Data included 594 patients
with ET, 538 with PV, and 293 with MF (61% primary MF; 23%
post-ETMF; 15% post-PVMF; eight missingMPN data).
Patients were of age (mean, 62 years; range, 20 to 94 years) and
sex (54%female) commonto thedisease (Table1). Laboratory abnor-
malities of anemia, thrombocytopenia, and leukopenia were most
prominent in patients with MF. Patients were an average of 6.7 years
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(range, 0 to 43 years) out from diagnosis of MPN at survey comple-
tion. Sixty-eight percent of patients were currently receiving cytore-
ductive therapy, most commonly hydroxyurea.
MPN-SAF TSS Burden of MPN Symptoms
TheMPNTSSwas calculable for 1,408patients (98%)with 1,214
completing all 10 items. Consistent with prior studies, themajority of
patients ( 50%) were symptomatic (score 0) in each MPN-SAF
TSS item except for items of bone pain (49%), weight loss (31%), and
fever (18%; Table 2). Fatigue carried the highest symptom intensity
(mean, 4.4; standard deviation [SD], 2.8), followed by problems with
concentration (mean, 2.5; SD, 2.8) and early satiety (mean, 2.5; SD,
2.7). More than one third of patients (35%) endorsed having a clini-
cally deficient QOL ( four of 10), with patients who had MF
Table 1. Demographic, Laboratory, and Historical Characteristics of Patients by MPN Type
Characteristic
No. of
Patients
ET (n  594) PV (n  538) MF (n  293)
% Mean SD % Mean SD % Mean SD
No. of patients with known MPN type 1,425
Age, years 60.7 14.5 62.8 13.1 63.5 11.5
Range 20-94 22-91 26-89
Female sex 64 46 47
Language
Italian 186 47 37 16
English 157 29 26 45
Swedish 114 46 46 7
French 477 48 37 16
Spanish 196 48 30 22
German 59 24 39 37
Dutch 236 31 50 19
Laboratory abnormalities
Anemia 7.4 3.4 49
Leukopenia 3.9 3.9 9.8
Thrombocytopenia 3.1 7.7 26
Circulating blasts 0.6 1.1 20
Any laboratory abnormality 13 12 59
Prior thrombohemorrhagic events or spleen-related symptoms
Average spleen size, cm (below costal margin) 0.8 3.0 2.5 5.1 7.4 7.2
Prior splenectomy 1.1 0.7 3.9
Thrombosis 21 30 14
Hemorrhage 3.5 7.7 7.1
Requiring red cell transfusions 1.4 1.3 23
Abbreviations: ET, essential thrombocythemia; MF, myelofibrosis; MPN, myeloproliferative neoplasm; PV, polycythemia vera; SD, standard deviation.
Table 2. Patient’s Assessment of Symptom Severity and Symptom Incidence by Disease Type (n  1,425 with known MPN type)
Symptom
ET (n  594) PV (n  538) MF (n  293) Total (n  1,425)
Mean SD Incidence (%) Mean SD Incidence (%) Mean SD Incidence (%) Mean SD Incidence (%)
Worst fatigue (one-item BFI) 4.1 2.8 87 4.4 2.9 88 5.0 2.6 96 4.4† 2.8 89†
Early satiety 2.2 2.7 59 2.5 2.7 64 3.2 2.8 77 2.5† 2.7 64†
Abdominal discomfort 1.7 2.3 50 1.6 2.3 51 2.5 2.7 66 1.8† 2.4 54†
Inactivity 1.9 2.5 56 2.4 2.7 61 3.1 2.8 74 2.4† 2.7 62†
Concentration problems 2.3 2.7 59 2.7 2.9 65 2.6 2.8 69 2.5† 2.8 63†
Night sweats 2.0 2.8 50 2.1 2.8 52 2.6 2.9 62 2.1† 2.8 53†
Itching 1.7 2.6 46 2.8 3.2 62 2.0 2.9 50 2.2† 2.9 53†
Bone pain 1.7 2.7 46 2.0 2.7 50 2.2 2.9 52 1.9† 2.8 49
Fever 0.3 1.1 17 0.4 1.1 18 0.5 1.3 22 0.4 1.2 18
Weight loss 0.8 2.0 24 1.0 2.1 31 1.7 2.7 42 1.1† 2.2 31†
MPN-SAF TSS 18.7 15.3 — 21.8 16.3 — 25.3 17.2 — 21.2† 16.3 —
NOTE. Symptom severity was rated on a 0 (absent/as good as it can be) to 10 (worst-imaginable/as bad as it can be) scale. Myeloproliferative Neoplasm Symptom
Assessment Form total symptom score (MPN-SAF TSS) has a possible range of 0 to 100 with 100 representing the highest level of symptom severity.
Abbreviations: BFI, Brief Fatigue Inventory; ET, essential thrombocythemia; MF, myelofibrosis; MPN, myeloproliferative neoplasm; PV, polycythemia vera; SD,
standard deviation.
Score  0.
†Comparisons of prevalence were evaluated by using 2 tests. Comparisons of severity were evaluated by using analysis of variance F tests. P .05 across groups.
MPN TSS as a Brief Measure of MPN Burden
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endorsing the greatest frequency of clinically deficient QOL (42%)
compared with patients who had ET or PV (30% and 38%, respec-
tively). More than half the patients rated their worst fatigue in the
previous 24 hours as moderate to severe ( four of 10; 60%). Overall
mean MPN-SAF TSS was 21.2 (SD, 16.3). Range of MPN-SAF TSSs
was 0 to 85 (Fig 1).
Known Groups Validity
MPN-SAF TSS significantly differed among MPN disease sub-
types (P  .001) with means of 18.7 (SD, 15.3), 21.8 (SD, 16.3), and
25.3 (SD, 17.2) for patients with ET, PV, andMF, respectively. Statis-
tically significant differences in MPN-SAF TSS results were also ob-
served between patients with clinically deficient ( four of 10;
n  480) versus nonclinically deficient QOL scores ( four of 10;
n 894; mean 33.2 v 14.7; P  .001). When compared with physi-
cians’ perceptions of patient symptoms, MPN-SAF TSS was signifi-
cantly higher in patients whose physicians rated two or more of six
common MPN-related symptoms as present (28.1; n 400) versus
fewer than two symptoms (15.5; n 726; P  .001). No significant
trends were observed when comparingMPN-SAF TSSs between cur-
rent medical therapy groups within each disease type.
Convergent Validity
The MPN-SAF TSS strongly correlated with patient-reported
overall QOL (r  0.59; P  .001). Strong correlations existed
between the MPN-SAF TSS and EORTC QLQ-C30 functional
scales (all P .001 and absolute r 0.50 except social functioning
[r 0.48]; Table 3). In addition, strong correlations were observed
between the MPN-SAF TSS and EORTC QLQ-C30 fatigue and
pain symptom scales (r  0.5; P  .001).
Internal Consistency and Construct Validity
The MPN-SAF TSS had excellent internal consistency (Cron-
bach’s   .83). Factor analysis identified a single underlying con-
struct among the 10 MPN-SAF TSS items (only a single eigenvalue
being 1). Factor loadings ranged from0.43 for fever andweight loss
to 0.71 for inactivity. The single factor suggests that the arithmetic
mean of the 10 items is an appropriate global MPN-SAF TSS.
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Fig 1.Myeloproliferative Neoplasm Symptom Assessment Form total symptom
scores (MPN-SAF TSS) represented by a histogram and overlaid normal distribu-
tion (mean and standard deviation based on sample estimates). (A) Total
symptom burden for all MPN-SAF TSS respondents completing at least five of 10
survey items (n  1,408). (B) Total symptom burden by MPN type. ET, essential
thrombocythemia; MF, myelofibrosis; PV, polycythemia vera.
Table 3. Pearson Correlations Between Selected MPN-SAF TSS Items and
Alternative Measures of MPN Disease Burden (n  1,408)
Item Measurement Instrument
Associated
Measure
Pearson
Correlation
Worst fatigue
(1-item
BFI)
QLQ-C30 Symptom Scale Fatigue 0.66
Overall QOL Overall QOL 0.53
Physicians’ perceptions Fatigue 0.51
Inactivity QLQ-C30 Functional Scale Physical 0.58
Role 0.60
Social 0.52
QLQ-C30 Symptom Scale Fatigue 0.59
Concentration QLQ-C30 Functional Scale Cognitive 0.63
QLQ-C30 Symptom Scale Fatigue 0.52
Overall QOL Overall QOL 0.53
Itching Physicians’ perceptions Itching 0.54
Bone pain QLQ-C30 Symptom Scale Pain 0.53
Weight loss Physicians’ perceptions Weight loss 0.54
MPN-SAF
TSS†
QLQ-C30 Functional Scale Physical 0.57
Role 0.51
Emotional 0.51
Global health/QOL 0.51
QLQ-C30 Symptom Scale Fatigue 0.65
Pain 0.56
Physicians’ perceptions Average physician’s
perception
0.51
Overall QOL Overall QOL 0.59
Abbreviations: BFI, Brief Fatigue Inventory; MPN, myeloproliferative neoplasm;
MPN-SAF TSS, Myeloproliferative Neoplasm Symptom Assessment Form total
symptom score; QLQ-C30, European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire C30; QOL, quality of life.
For all items, P  .001. Absolute value of Pearson correlation is reported.
†MPN-SAF TSS is the average score of worst fatigue, concentration, early
satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort,
weight loss, and fever.
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DISCUSSION
The MPN-SAF TSS is a valid and concise assessment of symptom
burden among patients with MPN in a variety of clinical settings.
The MPN-SAF TSS demonstrated excellent psychometric proper-
ties, including convergent validity, construct validity, differences
between known groups, and internal consistency. Being an abbre-
viated version of theMPN-SAF,5 the TSS captures the breadth and
intricacies of the overall symptom burden while enhancing the
research utility of the original survey. The MPN-SAF TSS also
demonstrated extensive global utility in assessing symptomburden
in a broad range of private and publicmedical care settings, includ-
ing recent use in the COMFORT I study [ControlledMyelofibrosis
Study with Oral JAK Inhibitor Treatment Comparing Ruxolitinib
to Placebo].9 This study incorporated a diverse cohort of patients
with ET, PV, andMF, representative of all stages of severity, includ-
ing a small cohort of patients with PV and ET who had obvious
disease progression.
The MPN-SAF TSS also represents the largest evaluation of
symptoms among an international, multilinguistic cohort of MPN
patients to date. This shortened scoring system will allow for serial
assessments capable of depicting a chronologic impression of symp-
tom burden. In addition, the clinical utility of the MPN-SAF may be
expanded when it is supplemented with physicians’ perceptions of
symptoms and other methods of symptom assessment such as the
EORTCQLQ-C30.8
We envision the MPN-SAF TSS as a useful tool in the clinical
practice setting when directing symptom therapy and monitoring
disease evolution. Although longitudinal evaluation of the MPN-
SAFTSS has not yet been validated, we believe serial assessments of
symptom burden may provide a sensitive clinical indicator of
disease progression. Thus far, our results suggest that the applica-
tion of conventional medical therapy (including hydroxyurea)
does not correlate with alterations in symptom burden. The prom-
ising disease-modifying effects of JAK2 inhibitors provide a unique
opportunity to use the MPN-SAF TSS in quantifying symptom
reduction. Anticipated studies include application of the MPN-
SAF TSS in evaluating the symptoms of bone marrow transplanta-
tion recipients, JAK2 inhibitor recipients, and patients receiving
other novel experimental therapies.
In conclusion, the MPN-SAF TSS appears to be an efficient,
sensitive, and reliable tool for assessing symptom burden in MPN
subpopulations. This instrument carries the potential to evaluate re-
sponse to treatment and track disease progression. With utility ex-
tending to both trial and clinical practice settings, we believe the
MPN-SAF TSS will prove to be an indispensable resource as we enter
this new era of gene-targeted therapies.
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